Can Helicobacter pylori infection cause elevated liver enzymes (transaminases)?

Can H. pylori Infection Cause Elevated Liver Enzymes?

Yes, H. pylori infection can cause elevated liver enzymes, and eradication therapy may lead to normalization of transaminase levels in patients with otherwise unexplained hypertransaminasemia.

Evidence from Guidelines

The Maastricht IV/Florence Consensus Report 1 does not specifically address liver enzyme elevation as a recognized extragastric manifestation of H. pylori infection. The guideline explicitly states that "the evidence available shows no unequivocal causative association between H pylori and other extragastric disorders" beyond iron-deficiency anemia, ITP, and vitamin B12 deficiency. However, this absence from major guidelines reflects the evolving nature of this association rather than definitive evidence against it.

Research Evidence Supporting the Association

Direct Evidence of Enzyme Normalization

A prospective study 2 of 107 patients with mild unexplained hypertransaminasemia and confirmed H. pylori infection demonstrated that after successful eradication (86.9% success rate):

• AST decreased by 6.3 ± 19.6 IU/L (P = 0.002)
• ALT decreased by 7.8 ± 24.9 IU/L (P = 0.001)
• 46.6% of patients with elevated AST normalized
• 45.7% of patients with elevated ALT normalized

This study specifically excluded viral hepatitis, metabolic causes, autoimmune hepatitis, drug/toxin-induced hepatitis, and fatty liver disease, strengthening the causal inference.

Mechanisms and Supporting Data

Recent mechanistic studies reveal how H. pylori affects liver function:

In metabolic dysfunction-associated steatotic liver disease (MASLD):

• H. pylori infection (particularly CagA-positive strains) significantly aggravates hepatic steatosis in high-fat diet models 3
• Transcriptomic analysis shows dysregulation of lipid metabolism pathways, particularly "fatty acid degradation" and "PPAR pathway" 3
• The infection exacerbates MASLD through hepatic lipid metabolic pathway disruption 3

In chronic hepatitis B:

• H. pylori co-infection correlates with higher AST levels (184.5 ± 37.6 U/L vs. 98.4 ± 23.5 U/L in H. pylori-negative patients, P < 0.01) 4
• Patients with HBV-DNA ≥10³ copies/ml had significantly higher H. pylori infection rates (76.8% vs. 52.4%, P < 0.001) 4
• H. pylori-positive patients showed worse Child-Pugh grades and more complications 4

Clinical Algorithm for Evaluation

When encountering mildly elevated transaminases (2-5× upper limit of normal) 5:

1. Rule out common causes first:

   • MASLD (most common)
   • Alcoholic liver disease
   • Chronic hepatitis B and C
   • Drug-induced liver injury
   • Hereditary hemochromatosis

2. If initial workup is negative, consider H. pylori testing:

   • Use validated stool antigen test (monoclonal antibody ELISA format) 1
   • Or ¹³C-urea breath test (gold standard) 1
   • Serology is acceptable if recent PPI/antibiotic use

3. If H. pylori positive with unexplained transaminase elevation:

   • Treat with bismuth quadruple therapy for 14 days 6
   • Confirm eradication 4 weeks post-treatment with stool antigen test or urea breath test 2
   • Recheck liver enzymes 4 weeks after successful eradication 2

Important Caveats

• The association is strongest in mild transaminase elevations (not severe hepatitis patterns)
• CagA-positive strains appear more hepatotoxic than CagA-negative strains 3
• Co-existing liver disease may be worsened by H. pylori rather than caused by it 4, 7
• The mechanism likely involves systemic inflammation, altered lipid metabolism, and possible direct bacterial translocation via portal circulation 8

Strength of Evidence

While major H. pylori guidelines have not yet incorporated liver enzyme elevation as a formal indication for testing and treatment, the research evidence is compelling:

• Prospective interventional data showing enzyme normalization after eradication 2
• Mechanistic studies demonstrating biological plausibility 3
• Multiple observational studies showing associations across different liver disease contexts 4, 7

In clinical practice, when faced with unexplained mild transaminase elevation after excluding standard causes, testing for and treating H. pylori is reasonable and may benefit approximately 45-47% of infected patients by normalizing their liver enzymes 2.